Collegium's ADHD drugs lift third-quarter sales as pain portfolio shrinks 18%

Collegium Pharmaceutical is leaning harder on attention-deficit medicines to replace falling pain revenue. Reporting third-quarter 2026 results on 5 November, the company said net product revenue rose 3% to $216.3M, the highest it has posted for a third quarter.

JORNAY PM brought in $51.9M, a 24% increase. AZSTARYS added $26.5M in what the company described as its first full quarter under Collegium ownership. The material reviewed does not say how or when Collegium acquired the product, and it gives no earlier sales figures for it.

The pain portfolio went the other way, dropping 18% to $138.0M. By our arithmetic, the two ADHD brands together generated about $78.4M, roughly 36% of quarterly net product revenue, while pain products still accounted for about 64%. The summary reviewed gives no year-earlier mix, so the size of the shift cannot be measured from these figures.

Collegium also reaffirmed its 2026 financial guidance and referred to a $50M accelerated share repurchase. The material available contains neither the guidance ranges nor the repurchase terms, so it is not possible to judge how much of the full-year outlook depends on the ADHD products.